Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera General Use Result Survey in Somatostatin Receptor-positive Neuroendocrine Tumor
jRCT2031230093Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET), sponsored by Novartis. Primary endpoints: Incidence of renal dysfunction, Incidence of myelosuppression and 2 more. Started Dec 2021; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on jRCT2031230093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230093.